5 Results for "

S1 binding pocket

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "S1 binding pocket" in MCE Product Catalog:

Cat. No.: HY-115741
CAS No.: 956025-99-3
Purity:  ≥99.0%
3BrB-PP1 is an ATP-competitive analog. 3BrB-PP1 can specifically inhibit the activity of protein kinase with mutations in the ATP-binding pocket (mutation of Thr97 within Sty1’s ATP-binding pocket) .
loading...
    loading...
Cat. No.: HY-168591
Target:  

Cathepsin

Research Areas:  

Cancer

CTSC-IN-1 (B22) is a CTSC inhibitor. CTSC-IN-1 inhibits CTSC activity by binding to S2 pocket and S1 site. CTSC-IN-1 can be used in the study inflammatory bowel disease .
loading...
    loading...
Cat. No.: HY-184117B
CAS No.: 3098808-75-1
Research Areas:  

Others

(R)-pMeO-Bz-SF, the R isomer of pMeO-Bz-SF (HY-184117), is an α-chymotrypsin inhibitor with an IC50 of 101 nM. (R)-pMeO-Bz-SF covalently modifies Ser195, Ser190, and Tyr146 in or near α-chymotrypsin’s hydrophobic S1 binding pocket. (R)-pMeO-Bz-SF inhibits α-chymotrypsin in a stereoselective manner .
loading...
    loading...
Cat. No.: HY-L925
9,365 compounds

Cysteine proteases (CPs), a key enzyme family regulating physiological metabolism and mediating pathological processes (such as abnormal bone resorption, tumour invasion, and pathogen infection), represent a core therapeutic target for developing specific inhibitors in disease intervention. Currently reported CP inhibitors primarily achieve their inhibitory function by precisely binding to CP active pockets (e.g., S1-S4 non-primed regions or S1'-S2' primed regions) and forming covalent/non-covalent interactions with the active site cysteine residues, providing clear structural references for the development of novel inhibitors.

This compound library, designed based on the core strategy of "similarity-based known active structures", contains over 200 cysteine protease inhibitors. Leveraging AI-driven molecular screening technology, it retains the critical pharmacological and shape features of reported CP inhibitors, serving as a specialized tool for efficiently discovering novel cysteine protease inhibitors.

Cat. No.: HY-184271
CAS No.: 3116900-85-4
Target:  

SphK Apoptosis

Research Areas:  

Cancer

SphK1-IN-5 is an orally active selective inhibitor of sphingosine kinase 1 (SphK1) with an IC50 of 0.87 μM and a Ki of 1.05 μM. SphK1-IN-5 directly binds to the ATP-binding pocket of SphK1 and enhances the thermal stability of this protein. SphK1-IN-5 regulates sphingolipid homeostasis: it increases sphingosine (Sph) levels and decreases sphingosine-1-phosphate (S1P) levels by inhibiting SphK1-mediated conversion of Sph to S1P. SphK1-IN-5 induces apoptosis in MC38 colon cancer cells, causes cell cycle arrest, inhibits cell migration, and exerts broad-spectrum antiproliferative effects against various tumor cells. SphK1-IN-5 exhibits antitumor activity in a mouse colon tumor model. SphK1-IN-5 can be used for research on colon cancer .
loading...
    loading...